eLife · 2020 · 431 citations · 41 references
MedicineInfectious Disease ControlInfectious DiseasesDisease PreventionEmerging Infectious DiseasesEpidemiologyDisease ControlInfectious Disease PreventionInfectious Disease ScreeningInfectious Disease SurveillanceOutbreak ResponsePopulation ScreeningEarly Disease ScreeningEmergenceEvidence Informed PolicyHigh-risk Symptom ScreeningScreening Program ImplementationSurveillance Screening
Traveller screening is used to limit COVID‑19 spread, and a prior model examined factors influencing its effectiveness. The study estimates how different screening programs affect COVID‑19 spread using current epidemiological data. The authors model various screening strategies based on known COVID‑19 incubation, symptom onset, and transmission parameters. Even under best‑case assumptions, screening misses more than half of infected individuals, mainly those who are asymptomatic or unaware of exposure, underscoring the need for additional measures and informing evidence‑based policy.
Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens.
41
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Kin‐Hang Kok et al. · The Lancet · 2020 · 9.6K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +13